• Aurora Cannabis published its fiscal 2026 MD&A, highlighting a strategic pivot toward global medical cannabis while winding down most Canadian consumer activity.
• Fiscal 2027 outlook calls for total net revenue to decline toward fiscal 2025 levels, with growth in Germany and Poland partly offsetting Canadian medical pressure.
• Adjusted gross margin before fair value adjustments forecast in the mid-to-high 50% range, supported by Europe mix and exits from lower-margin businesses.
• MD&A details expansion at Leuna, Germany, with about CAD 6 million spent; about CAD 3 million remaining; project expected to double annual output.
• Safari Flower acquisition closed for CAD 26.5 million, adding a 59,000-square-foot EU-GMP facility intended to reduce reliance on third-party purchases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurora Cannabis Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.